Geron Corporation (NASDAQ:GERN) received a Buy rating from Needham with a price target of $5 after reporting strong second quarter results. RYTELO sales exceeded expectations, with net product revenue of $49 million, a 24% increase from the previous quarter. Demand for RYTELO grew by 17% in the second quarter, driven by new patient starts. The company also appointed Harout Semerjian as the new CEO. Geron Corporation focuses on developing therapies for blood cancers. While GERN shows promise as an investment, certain AI stocks may offer greater potential. For more information, visit Insider Monkey.

Read more at Yahoo Finance: Needham Keeps Buy Rating on Geron (GERN) After Q2 Results